A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 25 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-24.
Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 18 in phase 2, and was the 1st registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre Hospitalier St Anne · Sites in France
Ages 18+
Beersheva Mental Health Center · Sites in Israel
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 3
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 30 across the 25 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 25 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing psilocybin in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT07183748Beersheva Mental Health CenterPsilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Low dose Psilocybin
Drug: Psilocybin
Medium dose Psilocybin
Drug: Psilocybin
High dose Psilocybin
Drug: Psilocybin
Dose-finding
Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3
MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.
Time frame: Change from Baseline to Week 3
MADRS Change From Baseline to Week 3, Sensitivity Analysis
MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.
Time frame: Change from Baseline to Week 3
First patient first visit: 1 March 2019 Last patients last visit: 27 September 2021
| Milestone | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin |
|---|---|---|---|
| Started | 79 | 75 | 79 |
| Completed | 74 | 66 | 69 |
| Not completed | 5 | 9 | 10 |
MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.
| units on a scale | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin |
|---|---|---|---|
| Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3 | -12 ± 12.98 | -8.9 ± 10.94 | -6.8 ± 11.10 |
MADRS is a clinician-rated scale measuring depression symptom severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of between 0 to 60; higher scores denote greater severity. Response \>= 50% decrease and remission \<= 10 total score.
| units on a scale | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin |
|---|---|---|---|
| MADRS Change From Baseline to Week 3, Sensitivity Analysis | -12 ± 12.98 | -8.9 ± 11.11 | -6.7 ± 11.18 |
Collected over Up to 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 25 mg COMP360 Psilocybin | 0/79 (0%) | 5/79 (6.3%) | 60/79 (75.9%) |
| 10 mg COMP360 Psilocybin | 0/75 (0%) | 6/75 (8%) | 51/75 (68%) |
| 1 mg COMP360 Psilocybin | 0/79 (0%) | 1/79 (1.3%) | 50/79 (63.3%) |
| Event | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin |
|---|---|---|---|
| Suicidal behaviourPsychiatric disorders | 3/79 | 0/75 | 0/79 |
| Intentional self-injuryPsychiatric disorders | 2/79 | 2/75 | 1/79 |
| Suicidal ideationPsychiatric disorders | 2/79 | 2/75 | 0/79 |
| DepressionPsychiatric disorders | 0/79 | 1/75 | 0/79 |
| HospitalisationSurgical and medical procedures | 0/79 | 1/75 | 0/79 |
| Drug withdrawal syndromeGeneral disorders | 1/79 | 0/75 | 0/79 |
| Adjustment disorder with anxietyPsychiatric disorders | 1/79 | 0/75 | 0/79 |
| Adjustment disorder with mixed anxiety and depressed moodPsychiatric disorders | 1/79 | 0/75 | 0/79 |
| Event | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin |
|---|---|---|---|
| HeadacheNervous system disorders | 27/79 | 16/75 | 20/79 |
| NauseaGastrointestinal disorders | 18/79 | 7/75 | 4/79 |
| InsomniaPsychiatric disorders | 8/79 | 11/75 | 14/79 |
| AnxietyPsychiatric disorders | 7/79 | 13/75 | 3/79 |
| FatigueGeneral disorders | 12/79 | 5/75 | 7/79 |
| Mood alteredPsychiatric disorders | 7/79 | 3/75 | 1/79 |
| Back painMusculoskeletal and connective tissue disorders | 6/79 | 0/75 | 3/79 |
| DizzinessNervous system disorders | 6/79 | 1/75 | 1/79 |
| DepressionPsychiatric disorders | 4/79 | 5/75 | 5/79 |
| Euphoric moodPsychiatric disorders | 4/79 | 5/75 | 4/79 |
The Safety Analysis Set included all randomised participants who received study drug.
| Age, Categorical(Participants) | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 76 | 73 | 77 | 226 |
| >=65 years | 3 | 2 | 2 | 7 |
| Age, Continuous(years) | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin | Total |
|---|---|---|---|---|
| Mean | 40.2 ± 12.19 | 40.6 ± 12.76 | 38.7 ± 11.71 | 39.8 ± 12.19 |
| Sex: Female, Male(Participants) | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin | Total |
|---|---|---|---|---|
| Female | 35 | 34 | 43 | 112 |
| Male | 44 | 41 | 36 | 121 |
| Race (NIH/OMB)(Participants) | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 3 | 5 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 1 | 5 |
| White | 70 | 72 | 73 | 215 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | 25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin | Total |
|---|---|---|---|---|
| Canada | 2 | 2 | 2 | 6 |
| Netherlands | 17 | 16 | 17 | 50 |
| United States | 32 | 32 | 32 | 96 |
| Czechia | 3 | 2 | 2 | 7 |
| Ireland | 3 | 3 | 5 | 11 |
| Denmark | 3 | 2 | 3 | 8 |
| United Kingdom | 11 | 10 | 12 | 33 |
| Portugal | 1 | 0 | 1 | 2 |
| Germany | 2 | 2 | 0 | 4 |
| Spain | 5 | 6 | 5 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Jul 2021, 28 months.
Results were first posted in Apr 2023, 1 year 8 months after primary completion.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Depressive Disorder, Treatment-Resistant →
COMPASS Pathways